JPH06211632A - Hair-growing agent - Google Patents
Hair-growing agentInfo
- Publication number
- JPH06211632A JPH06211632A JP634593A JP634593A JPH06211632A JP H06211632 A JPH06211632 A JP H06211632A JP 634593 A JP634593 A JP 634593A JP 634593 A JP634593 A JP 634593A JP H06211632 A JPH06211632 A JP H06211632A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- kinetin
- derivative
- alopecia
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 claims abstract description 33
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960001669 kinetin Drugs 0.000 claims abstract description 33
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims abstract description 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 8
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims abstract description 8
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229950003631 carpronium chloride Drugs 0.000 claims abstract description 7
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000810 peripheral vasodilating agent Substances 0.000 claims abstract description 7
- 229960002116 peripheral vasodilator Drugs 0.000 claims abstract description 7
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims abstract description 6
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 6
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 229960003632 minoxidil Drugs 0.000 claims abstract description 6
- 210000004209 hair Anatomy 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 239000003504 photosensitizing agent Substances 0.000 claims description 4
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 201000004384 Alopecia Diseases 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 12
- 231100000360 alopecia Toxicity 0.000 abstract description 7
- 208000004631 alopecia areata Diseases 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 1
- 241001615463 Trichogenes Species 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003779 hair growth Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- -1 pantothenyl ethyl alcohol Chemical compound 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 229930007845 β-thujaplicin Natural products 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 239000006000 Garlic extract Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000021302 avocado oil Nutrition 0.000 description 2
- 239000008163 avocado oil Substances 0.000 description 2
- 229950004580 benzyl nicotinate Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940008396 carrot extract Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000020706 garlic extract Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 150000002948 pantothenic acids Chemical class 0.000 description 2
- 230000008635 plant growth Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- SERLAGPUMNYUCK-URHLDCCQSA-N (2R,3S,4R,5S)-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-URHLDCCQSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- SWFHGTMLYIBPPA-UHFFFAOYSA-N (4-methoxyphenyl)-phenylmethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 SWFHGTMLYIBPPA-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- FRCHKSNAZZFGCA-UHFFFAOYSA-N 1,1-dichloro-1-fluoroethane Chemical compound CC(F)(Cl)Cl FRCHKSNAZZFGCA-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- GANBJDIOIDQSGI-UHFFFAOYSA-N 2-(chloromethyl)furan Chemical compound ClCC1=CC=CO1 GANBJDIOIDQSGI-UHFFFAOYSA-N 0.000 description 1
- NDNMXRYLRJEZAR-UHFFFAOYSA-N 2-[1-(4-methoxyphenyl)propylidene]octanoic acid Chemical compound CCCCCCC(C(O)=O)=C(CC)C1=CC=C(OC)C=C1 NDNMXRYLRJEZAR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UIJIQXGRFSPYQW-UHFFFAOYSA-N 6-methylthiopurine Chemical compound CSC1=NC=NC2=C1N=CN2 UIJIQXGRFSPYQW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229920001755 Kefiran Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 229940071120 dehydroacetate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical group CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、発毛促進に卓越した効
果を有する育毛剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hair restorer having an excellent effect on promoting hair growth.
【0002】[0002]
【従来の技術】従来種々の育毛剤が、禿頭、薄毛に対
し、その予防や治療に用いられてきている。一般に、育
毛剤に配合されている成分は、主に頭皮の血行促進、頭
皮の清浄化、消炎および殺菌、毛包および毛包周辺の細
胞の酵素の賦活化、毛母細胞のエネルギー代謝の改善、
頭皮での男性ホルモン作用の抑制を目的としている。2. Description of the Related Art Conventionally, various hair-growing agents have been used for preventing and treating baldness and thinning hair. Generally, the ingredients contained in hair restorers are mainly scalp blood circulation promotion, scalp cleaning, anti-inflammatory and sterilization, activation of enzymes in hair follicles and cells around hair follicles, improvement of energy metabolism of hair mother cells. ,
The purpose is to suppress male hormone action in the scalp.
【0003】例えば、塩化カルプロニウム、ビタミン
E、トウガラシエキス、センブリエキス、ニンニクエキ
スなどは、末梢血管拡張剤作用によって毛包部の血流量
を増加させ、毛母細胞を賦活化しようとするものであ
り、ヒノキチオール、レゾルシンなどの殺菌剤やグリチ
ルリチン、アラントインなどの消炎剤は、脱毛の一因と
なることが知られている頭皮部分の炎症を抑制するため
に、炎症の原因となる細菌によるフケや皮脂の分解物の
生成あるいは炎症を防ぐ目的で、ビタミンA群、ビタミ
ンB群、ビオチン、パントテン酸誘導体などのビタミン
類は、毛母細胞の酵素を賦活化し毛の合成を促進する目
的で、さらに、エストラジオール、エチニルエストラジ
オールなどの女性ホルモンは、男性型脱毛症の主因と考
えられる男性ホルモンの作用を抑制するために用いられ
てきた。[0003] For example, carpronium chloride, vitamin E, capsicum extract, assembly extract, garlic extract, etc. are intended to increase the blood flow in the hair follicle portion by the action of peripheral vasodilator and activate hair matrix cells. , Antibacterial agents such as hinokitiol and resorcin, and anti-inflammatory agents such as glycyrrhizin and allantoin are known to contribute to hair loss. To suppress inflammation of the scalp part, dandruff and sebum caused by bacteria that cause inflammation Vitamin A group, vitamin B group, biotin, pantothenic acid derivative, and other vitamins for the purpose of activating the enzymes of hair matrix cells and promoting hair synthesis. Female hormones such as estradiol and ethinyl estradiol are considered to be the main causes of male pattern baldness. It has been used to inhibit the action.
【0004】[0004]
【発明が解決しようとする課題】しかしながら、上述し
た従来の育毛剤成分は、ある程度の発毛促進効果や脱毛
予防効果が認められるものの、いずれもその効果は満足
できるものではなく、特に発毛促進効果が不十分であっ
た。However, although the above-described conventional hair-growth agent components have some hair-growth-promoting effects and hair loss-preventing effects, none of them are satisfactory, and hair-growth-promoting effects are particularly high. The effect was insufficient.
【0005】[0005]
【発明の目的】そこで本発明の目的は、頭皮に適用する
ことにより、毛髪の発育促進に卓越した効果を発揮する
ことのできる育毛剤を提供することにある。OBJECTS OF THE INVENTION It is therefore an object of the present invention to provide a hair-growth agent which, when applied to the scalp, can exert an excellent effect in promoting hair growth.
【0006】[0006]
【課題を解決するための手段】本発明は、前記目的を達
成するために提案されたものであり、従来から、植物生
長調節物として植物の生育に利用され、特開昭48−3
9646号公報に見られるように、乾燥皮膚をしっとり
させる化粧料としての利用が知られているカイネチン
が、驚くべきことに育毛効果を有しているという本発明
者によって始めて得られた知見を元に完成されたもので
ある。The present invention has been proposed in order to achieve the above-mentioned object, and has been conventionally used as a plant growth regulator for plant growth.
As can be seen in Japanese Patent No. 9646, kinetin, which is known to be used as a cosmetic for moisturizing dry skin, has a surprising finding that it has a hair-growing effect. It was completed in.
【0007】すなわち、本発明によれば、カイネチンを
有効成分とすることを特徴とする育毛剤が提供される。
前記カイネチンは、サイクリックアデノシンモノフォス
フェートおよびその誘導体、サイクリックグアノシンモ
ノフォスフェートおよびその誘導体、フォルスコリン、
塩化カルプロニウム、ペンタデカン酸グリセリド、ミノ
キシジル、女性ホルモン、ビタミン類、末梢血管拡張
剤、細胞賦活剤、ならびに感光素からなる群より選ばれ
る1種以上の化合物と併用されることにより、その育毛
効果が一層卓越したものになる。[0007] That is, according to the present invention, there is provided a hair restorer characterized by containing kinetin as an active ingredient.
The kinetin includes cyclic adenosine monophosphate and its derivative, cyclic guanosine monophosphate and its derivative, forskolin,
The hair-growth effect is further enhanced by the combined use of one or more compounds selected from the group consisting of carpronium chloride, pentadecanoic acid glyceride, minoxidil, female hormones, vitamins, peripheral vasodilators, cell activating agents, and photosensitizers. It will be outstanding.
【0008】[0008]
【発明の具体的な説明】脱毛症の原因は、詳細には解明
されていないが、毛乳頭、毛包周辺の血液循環障害、男
性ホルモン作用、遺伝、栄養障害、内分泌異常、精神的
ストレスなどが関与するといわれている。本発明者ら
は、前述した脱毛症のさまざまな要因を分析し、それら
を排除するために、数多くの化合物について鋭意研究を
重ねてきた。その結果、前述したように、従来から、生
長調節物として植物の生育に利用され、乾燥皮膚をしっ
とりさせる化粧料としての利用が知られているカイネチ
ンが発毛促進に卓越した効果を有すること、また、男性
型脱毛症や円形脱毛症などの脱毛症に対して脱毛治療効
果も有することを見いだし、本発明を完成したものであ
る。[Detailed Description of the Invention] The cause of alopecia has not been elucidated in detail, but it is impaired in blood circulation around the papillae and follicles, androgen action, inheritance, nutritional disorders, endocrine disorders, mental stress, etc. Are said to be involved. The present inventors have conducted various studies on many compounds in order to analyze various factors of the above-mentioned alopecia and eliminate them. As a result, as described above, kinetin, which is conventionally used as a growth regulator for plant growth and is known to be used as a cosmetic to moisturize dry skin, has an excellent effect on promoting hair growth, Further, they have found that it also has a hair loss treatment effect on alopecia such as androgenetic alopecia and alopecia areata, and completed the present invention.
【0009】カイネチンは、プリンの誘導体で、6−フ
ルフリルアミノプリンとも呼ばれるものである。本発明
のカイネチンは、化学的に合成され、例えば、アデニン
とフルフリルクロライドとの反応、6−メチルメルカプ
トプリンとフルフリルアミンとの反応などによって得ら
れる。また、カイネチンは、例えば、ニシンの精子など
のDNAを多量に含む天然物を高圧加熱することによっ
ても得ることができる。このように本発明のカイネチン
は、化学合成法により合成されたものやDNAを多量に
含む天然物の高圧加熱物のいずれでも使用可能である。Kinetin is a derivative of purine and is also called 6-furfurylaminopurine. The kinetin of the present invention is chemically synthesized and obtained, for example, by a reaction between adenine and furfuryl chloride, a reaction between 6-methylmercaptopurine and furfurylamine, and the like. Kinetin can also be obtained, for example, by high-pressure heating a natural product containing a large amount of DNA such as herring sperm. As described above, the kinetin of the present invention can be used either as a substance synthesized by a chemical synthesis method or as a high pressure heated product of a natural product containing a large amount of DNA.
【0010】さらに、カイネチンは、サイクリックアデ
ノシンモノフォスフェートおよびその誘導体、、サイク
リックグアノシンモノフォスフェートおよびその誘導
体、フォルスコリン、塩化カルプロニウム、ペンタデカ
ン酸グリセリド、ミノキシジル、女性ホルモン、副腎皮
質ホルモン、ビタミン類、末梢血管拡張剤、細胞賦活
剤、ならびに感光素からなる群より選ばれる1種以上の
化合物を併用することによって、発毛促進及び脱毛症の
治療効果を一層高めることができる。Further, kinetin is cyclic adenosine monophosphate and its derivative, cyclic guanosine monophosphate and its derivative, forskolin, carpronium chloride, pentadecanoic acid glyceride, minoxidil, female hormone, adrenocortical hormone, vitamins. The combined use of one or more compounds selected from the group consisting of a peripheral vasodilator, a cell activating agent, and a photosensitizer can further enhance the effects of promoting hair growth and treating alopecia.
【0011】サイクリックアデノシンモノフォスフェー
ト(c−AMP)の誘導体およびサイクリックグアノシ
ンモノフォスフェート(c−GMP)の誘導体として
は、ジブチリルサイクリックアデノシンモノフォスフェ
ート(dbc−AMP)、8−ブロモサイクリックアデ
ノシンモノフォスフェート(8−Br−c−AMP)、
ジブチリルサイクリックグアノシンモノフォスフェート
(dbc−GMP)、8−ブロモサイクリックグアノシ
ンモノフォスフェート(8−Br−c−GMP)などを
例示することができる。Derivatives of cyclic adenosine monophosphate (c-AMP) and cyclic guanosine monophosphate (c-GMP) include dibutyryl cyclic adenosine monophosphate (dbc-AMP) and 8-bromo. Cyclic adenosine monophosphate (8-Br-c-AMP),
Examples thereof include dibutyryl cyclic guanosine monophosphate (dbc-GMP) and 8-bromocyclic guanosine monophosphate (8-Br-c-GMP).
【0012】女性ホルモンとしては、エストラジオール
およびそのエステル、エストロン、エチニルエストラジ
オール、ジエチルスチルベストロール、ヘキストロール
などを例示することができる。Examples of female hormones include estradiol and its ester, estrone, ethinyl estradiol, diethylstilbestrol, and hexstrol.
【0013】副腎皮質ホルモンとしては、コルチゾン、
ハイドロコルチゾン、プレドニゾロン、プレドニゾン、
9−α−ハイドロフルオロコルチゾンなどを例示するこ
とができる。As the corticosteroid, cortisone,
Hydrocortisone, prednisolone, prednisone,
Examples thereof include 9-α-hydrofluorocortisone.
【0014】ビタミン類としては、ビタミンA酸、13
−シスレチノイン酸、エトレチネートなどのビタミンA
群、ビタミンE、ビタミンEニコチネート、ビタミンE
アセテートなどのビタミンE群、ニコチン酸、ニコチン
酸アミド、ニコチン酸ベンジルなどのビタミンB群、パ
ントテン酸、パントテニルアルコール、パントテニルエ
チルアルコールなどのパントテン酸類、ビオチンなどを
例示できる。As vitamins, vitamin A acid, 13
-Vitamin A such as cis retinoic acid and etretinate
Group, vitamin E, vitamin E nicotinate, vitamin E
Examples thereof include vitamin E group such as acetate, vitamin B group such as nicotinic acid, nicotinic acid amide and benzyl nicotinate, pantothenic acids such as pantothenic acid, pantothenyl alcohol, and pantothenyl ethyl alcohol, and biotin.
【0015】末梢血管拡張剤としては、ショウキョウチ
ンキ、トウガラシチンキ、セファランチン、延命草、苦
参エキスなどを例示できる。Examples of the peripheral vasodilator include ginger tincture, capsicum tincture, cepharanthin, life-prolonging herbs, ginseng extract and the like.
【0016】細胞賦活剤としては、センブリエキス、ニ
ンニクエキス、ニンジンエキス、ローズマリーエキス、
アロエエキス、胎盤抽出液、竹節ニンジンエキス、干
姜、紅花、オウギ、桃仁、補骨脂、当帰、センキュウ、
丹参などの生薬を例示できる。As the cell activating agent, sea bream extract, garlic extract, carrot extract, rosemary extract,
Aloe extract, placenta extract, bamboo shoot carrot extract, ginger, safflower, ougi, peach kernel, bone replenisher, toki, senkyu,
An example is a crude drug such as Danshen.
【0017】感光素としては、感光素101、感光素2
01、感光素301、感光素401を例示できる。The photosensitive elements are a photosensitive element 101 and a photosensitive element 2.
01, the photosensitive element 301, and the photosensitive element 401 can be illustrated.
【0018】本発明の毛髪用外用剤は、医薬品、医薬部
外品、化粧品を含むものであり、その剤型としては外用
可能な種々の形態、例えばクリーム、ローション、乳
剤、軟膏、ゲル、ヘアトニック、ヘアリキッド、リニメ
ント、ヘアーリンス、ヘアーシャンプー、ヘアートリー
トメント、ヘアーコンディショナー、エアゾール、ムー
スなどの公知の形態に製剤化して使用でき、その基剤も
毛髪施用上許容し得る任意の液状及び固形状の原料を幅
広く使用できる。その際、必要に応じてカイネチンの育
毛効果を損なわない範囲で、公知の白髪防止剤、殺菌抗
炎症剤、香料、安定剤、着色剤、紫外線吸収剤、酸化防
止剤、保湿剤、増粘剤などの種々の添加剤を加えること
もできる。The external preparation for hair of the present invention includes pharmaceuticals, quasi-drugs and cosmetics, and its dosage forms include various externally applicable forms such as cream, lotion, emulsion, ointment, gel and hair. It can be used by formulating it into a known form such as tonic, hair liquid, liniment, hair rinse, hair shampoo, hair treatment, hair conditioner, aerosol and mousse, and its base is any liquid or solid form acceptable for hair application. A wide range of raw materials can be used. At that time, if necessary, within a range that does not impair the hair-growing effect of kinetin, a known anti-hair graying agent, bactericidal anti-inflammatory agent, fragrance, stabilizer, coloring agent, ultraviolet absorber, antioxidant, moisturizer, thickener It is also possible to add various additives such as.
【0019】殺菌抗炎症剤としては、例えば、イソプロ
ピルメチルフェノール、塩酸ジフェンヒドラミン、グリ
チルリチン酸誘導体、ヒノキチオール、安息香酸塩、サ
リチル酸塩、ソルビン酸塩、デヒドロ酢酸塩、パラオキ
シ安息香酸エステル、2,4,4’−トリクロロ−2’
−ヒドロキシジフェニルエーテル、3,4,4’−トリ
クロロカルバニド、塩化ベンザルコニウム、レゾルシ
ン、エタノール、ウンデシレン酸などを例示することが
できる。Examples of bactericidal anti-inflammatory agents include isopropylmethylphenol, diphenhydramine hydrochloride, glycyrrhizic acid derivative, hinokitiol, benzoate, salicylate, sorbate, dehydroacetate, paraoxybenzoate, 2,4,4. '-Trichloro-2'
-Hydroxydiphenyl ether, 3,4,4'-trichlorocarbanide, benzalkonium chloride, resorcin, ethanol, undecylenic acid and the like can be exemplified.
【0020】安定剤としては、例えば、エチレンジアミ
ン四酢酸塩、ピロリン酸塩、ヘキサメタリン酸塩、クエ
ン酸塩、酒石酸、グルコン酸などのキレート剤のほか、
水酸化ナトリウム、リン酸水素カリウムなどのpH調整
剤をそれぞれ例示することができる。Examples of the stabilizer include chelating agents such as ethylenediaminetetraacetate, pyrophosphate, hexametaphosphate, citrate, tartaric acid and gluconic acid.
Examples of pH adjusting agents such as sodium hydroxide and potassium hydrogen phosphate can be given.
【0021】紫外線吸収剤としては、例えば、4−メト
キシベンゾフェノン、オクチルジメチルパラアミノベン
ゾエート、エチルヘキシルパラメトキシサイナメート、
酸化チタン、カオリン、タルク等を例示することができ
る。Examples of the ultraviolet absorber include 4-methoxybenzophenone, octyldimethylparaaminobenzoate, ethylhexylparamethoxycinnamate,
Titanium oxide, kaolin, talc, etc. can be illustrated.
【0022】酸化防止剤としては、例えば、ジブチルヒ
ドロキシトルエン、ブチルヒドロキシアニソール、没食
子酸プロピルなどを例示することができる。Examples of the antioxidant include dibutylhydroxytoluene, butylhydroxyanisole, propyl gallate and the like.
【0023】保湿剤としては、例えば、グリセリン、プ
ロピレングリコール、1,3ブチレングリコール、ソル
ビトール、マンニトール、ポリエチレングリコール、ジ
プロピレングリコールなどの多価アルコール類、アミノ
酸、乳酸ナトリウム、ピロリドンカルボン酸ナトリウム
などのNMF成分、ヒアルロン酸、コラーゲン、エラス
チン、コンドロイチン硫酸、デルマタン硫酸、フィブロ
ネクチン、セラミド類、ヘパリン類似様物質、キトサン
等の水溶性高分子物質、ササニシキエキス、冬虫夏草、
デュークエキスなどを例示することができる。Examples of moisturizers include polyhydric alcohols such as glycerin, propylene glycol, 1,3 butylene glycol, sorbitol, mannitol, polyethylene glycol and dipropylene glycol, NMF such as amino acids, sodium lactate and sodium pyrrolidonecarboxylate. Ingredients, hyaluronic acid, collagen, elastin, chondroitin sulphate, dermatan sulphate, fibronectin, ceramides, heparin-like substances, water-soluble polymeric substances such as chitosan, sasanishiki extract, Cordyceps sinensis,
Duke extract etc. can be illustrated.
【0024】さらに、増粘剤としては、例えば、アルギ
ン酸ナトリウム、キサンタンガム、ケイ酸アルミニウ
ム、マルメロ種子抽出物、トラガントゴム、デンプン、
ケフィラン等の天然高分子物質、メチルセルロース、ヒ
ドロキシエチルセルロース、カルボキシメチルセルロー
ス、可溶性デンプン、カチオン化セルロース等の半合成
高分子物質、カルボキシビニルポリマー、ポリビニルア
ルコール等の合成高分子物質などを例示することができ
る。Further, as the thickener, for example, sodium alginate, xanthan gum, aluminum silicate, quince seed extract, tragacanth gum, starch,
Examples thereof include natural polymer substances such as kefiran, semi-synthetic polymer substances such as methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, soluble starch and cationized cellulose, and synthetic polymer substances such as carboxyvinyl polymer and polyvinyl alcohol.
【0025】本発明の育毛剤の有効成分であるカイネチ
ンの配合量は、症状の度合、剤型などによって適宜変更
してよいが、通常0.001ないし20重量%程度、好
ましくは0.1ないし10重量%程度を製剤中に配合す
る。また、カイネチンと併用して用いる成分の配合量
は、通常0.01ないし20重量%程度、好ましくは
0.1ないし10重量%程度を製剤中に配合する。The amount of kinetin, which is an active ingredient of the hair restorer of the present invention, may be appropriately changed depending on the degree of symptoms, dosage form and the like, but is usually about 0.001 to 20% by weight, preferably 0.1 to. About 10% by weight is added to the formulation. The amount of the component used in combination with kinetin is usually about 0.01 to 20% by weight, preferably about 0.1 to 10% by weight.
【0026】[0026]
【実施例】次に本発明の育毛剤の処方例ならびにその効
果の試験例を挙げるが、これは本発明を何ら限定するも
のではない。なお処方例中、「適量」とは、処方全量が
100重量%になる量を意味する。[Examples] Next, formulation examples of the hair-growth agent of the present invention and test examples of its effect will be shown, but these do not limit the present invention at all. In the prescription examples, "appropriate amount" means an amount that makes the total prescription amount 100% by weight.
【0027】 <処方例1> ヘアークリーム (重量%) A 流動パラフィン 10.0 スクワラン 7.0 ホホバ油 3.0 固型パラフィン 3.0 ポリオキシエチレンセチルエーテル 2.0 ソルビタンセスキオレエート 1.0 水酸化カリウム 0.1 ミノキシジル 0.5 カイネチン 5.0 B グリセリン 3.0 エチルパラベン 0.1 精製水 適量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加熱溶解する。AにBを添加して撹拌、乳化後、冷却
してヘアークリームを製造した。<Formulation Example 1> Hair cream (% by weight) A Liquid paraffin 10.0 Squalane 7.0 Jojoba oil 3.0 Solid paraffin 3.0 Polyoxyethylene cetyl ether 2.0 Sorbitan sesquioleate 1.0 Potassium hydroxide 0.1 Minoxidil 0.5 Kinetin 5.0 B Glycerin 3.0 Ethyl Paraben 0.1 Purified water Appropriate amount The ingredients belonging to A are dissolved by heating. Separately, the components belonging to B are melted by heating. After adding B to A, stirring and emulsifying, cooling was carried out to produce a hair cream.
【0028】 <処方例2> ヘアートニック (重量%) A ポリオキシエチレン硬化ヒマシ油 1.0 dbc−AMP 1.0 イソプロピルメチルフェノール 0.05 エタノール 55.0 カイネチン 4.0 B グリセリン 2.0 精製水 適量 Aに属する成分を均一に撹拌、溶解し、別に均一に溶解
したBに属する成分を徐々に加え、均一に撹拌してヘア
ートニックを製造した。<Formulation Example 2> Heartonic (% by weight) A Polyoxyethylene hydrogenated castor oil 1.0 dbc-AMP 1.0 Isopropylmethylphenol 0.05 Ethanol 55.0 Kinetin 4.0 B Glycerin 2.0 Purified water Appropriate amount A component belonging to A is uniformly stirred and dissolved. Then, separately, the components belonging to B, which were uniformly dissolved, were gradually added, and the mixture was uniformly stirred to produce a hair nick.
【0029】 <処方例3> ヘアートリートメント (重量%) A アボカド油 5.0 スクワラン 5.0 流動パラフィン 10.0 ステアリン酸 3.0 グリセリンモノステアレート 3.0 ラノリンアルコール 5.0 カイネチン 2.0 B センブリ抽出液 1.0 1,3−ブチレングリコール 5.0 トリエタノールアミン 1.0 メチルパラベン 0.2 精製水 適量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加熱溶解する。AにBを添加して撹拌、乳化後、冷却
してヘアートリートメントを製造した。<Formulation Example 3> Hair treatment (% by weight) A Avocado oil 5.0 Squalane 5.0 Liquid paraffin 10.0 Stearic acid 3.0 Glycerin monostearate 3.0 Lanolin alcohol 5.0 Kinetin 2.0 B Assemblage extract 1.0 1,3-Butylene glycol 5.0 Triethanol Amine 1.0 Methylparaben 0.2 Purified water Appropriate amount A component belonging to A is dissolved by heating. Separately, the components belonging to B are melted by heating. After adding B to A, stirring, emulsifying, and cooling, a hair treatment was manufactured.
【0030】 <処方例4> ヘアーシャンプー (重量%) A フォルスコリン 0.05 N−ヤシ油脂肪酸−L−グルタミン酸 40.0 トリエタノールアミン(30%) ヤシ油脂肪酸ジエタノールアミド 3.0 ポリオキシエチレンジオレイン酸メチル 2.0 グルコシド(120E.O.) カイネチン 2.5 B パラオキシ安息香酸エテル 0.3 エデト酸ニナトリウム 0.1 精製水 適量 Aに属する成分を均一に撹拌、溶解し、別に均一に加温
溶解したBに属する成分を徐々に加え、均一に撹拌して
ヘアーシャンプを製造した。<Formulation Example 4> Hair shampoo (% by weight) A Forskolin 0.05 N-coconut oil fatty acid-L-glutamic acid 40.0 Triethanolamine (30%) Coconut oil fatty acid diethanolamide 3.0 Polyoxyethylene methyl dioleate 2.0 Glucoside (120 EO) Kinetin 2.5 B Ethyl paraoxybenzoate 0.3 Disodium edetate 0.1 Purified water Appropriate amount A component belonging to A is uniformly stirred and dissolved, and separately heated and uniformly added to a component belonging to B, A hair shampoo was prepared by stirring uniformly.
【0031】 <処方例5> エアゾール (重量%) A ニコチン酸ベンジル 0.01 ビタミンEアセテート 0.05 セタノール 1.2 カイネチン 0.05 プロピレングリコール 4.0 エタノール 8.0 精製水 適量 B フロン123/141b(57:43) 7.0 Aに属する成分を均一に混合溶解してエアゾール容器に
入れ、常法によりBを容器に充填してエアゾールを製造
した。<Formulation Example 5> Aerosol (wt%) A Benzyl nicotinate 0.01 Vitamin E acetate 0.05 Cetanol 1.2 Kinetin 0.05 Propylene glycol 4.0 Ethanol 8.0 Purified water Appropriate amount B Freon 123 / 141b (57:43) 7.0 A component belonging to A The mixture was uniformly mixed and dissolved, placed in an aerosol container, and B was filled in the container by an ordinary method to produce an aerosol.
【0032】 <処方例6> エアフォーム (重量%) A ヒノキチオール 0.1 セタノール 1.2 プロピレングリコール 2.0 ジメチルシリコーン油 2.0 ポリオキシエチレン硬化ヒマシ油 2.5 流動パラフィン 1.0 ポリビニルピロリドン 0.5 カイネチン 3.0 メチルパラベン 0.2 エタノール 10.0 精製水 適量 B 液化石油ガス(噴射剤) 4.0 Aに属する成分を均一に混合して容器に入れ、常法によ
りBを容器に充填してエアフォームを製造した。<Formulation Example 6> Air foam (% by weight) A Hinokitiol 0.1 Cetanol 1.2 Propylene glycol 2.0 Dimethyl silicone oil 2.0 Polyoxyethylene hydrogenated castor oil 2.5 Liquid paraffin 1.0 Polyvinylpyrrolidone 0.5 Kinetin 3.0 Methylparaben 0.2 Ethanol 10.0 Purified water qs B Liquefaction Petroleum gas (propellant) 4.0 Ingredients belonging to A were uniformly mixed and placed in a container, and B was filled in the container by an ordinary method to produce an air foam.
【0033】 <処方例7> ヘヤーリキッド (重量%) A ポリオキシプロピレンブチルエーテル(40P.0.) 15.0 ジイソプロパノールアミン 0.5 カイネチン 8.0 エタノール 50.0 B プロピレングリコール 3.0 精製水 適量 常温でAに属する成分を均一に撹拌、溶解し、別に均一
に溶解したBに属する成分を徐々に加え、均一に撹拌し
てヘアーリキッドを製造した。<Formulation Example 7> Hair liquid (% by weight) A Polyoxypropylene butyl ether (40 P.0.) 15.0 Diisopropanolamine 0.5 Kinetin 8.0 Ethanol 50.0 B Propylene glycol 3.0 Purified water Appropriate amount of components belonging to A at room temperature A component belonging to B, which was stirred, dissolved, and uniformly dissolved, was gradually added, and the mixture was stirred uniformly to produce a hair liquid.
【0034】 <処方例8> ミルクローション (重量%) A ポリオキシエチレンベヘニルエーテル(20E.0.) 0.5 テトラオレイン酸ポリオキシエチレンソルビット (60E.0.) 1.0 親油型モノステアリン酸グリセリン 1.0 ステアリン酸 1.5 ベヘニルエーテル 1.5 アボカド油 3.0 天然ビタミンE 0.02 塩化カルプロニウム 0.5 カイネチン 1.0 B 1,3ーブチレングリコール 5.0 精製水 適量 Aに属する成分を加熱溶解する。別に、Bに属する成分
を加熱溶解する。AにBを添加して撹拌、乳化後、冷却
してミルクローションを製造した。<Formulation Example 8> Milk lotion (wt%) A Polyoxyethylene behenyl ether (20E.0.) 0.5 Tetraoleic acid polyoxyethylene sorbit (60E.0.) 1.0 Lipophilic glyceryl monostearate 1.0 Stearin Acid 1.5 Behenyl ether 1.5 Avocado oil 3.0 Natural vitamin E 0.02 Carpronium chloride 0.5 Kinetin 1.0 B 1,3-Butylene glycol 5.0 Purified water Appropriate amount The ingredients belonging to A are dissolved by heating. Separately, the components belonging to B are melted by heating. After adding B to A, stirring and emulsifying, cooling was performed to produce a milk lotion.
【0035】[0035]
【試験例】マウス発毛効果試験 カイネチンの単独効果及びカイネチンと他の公知の有効
成分との併用効果を下記の方法を用いて調べた。 <試料>処方例8の基剤に、本発明の有効成分であるカ
イネチンを1%配合したものを用いた。対照には基剤の
みを、陽性対照として1%ペンタデカン酸グリセリドを
用いた。また、併用効果を調べる場合には、処方例8の
基剤に、カイネチンを0.3%及び公知の有効成分を所
定の濃度配合したものを用いた。[Test Example] Mouse hair growth effect test The effect of kinetin alone and the effect of combined use of kinetin with other known active ingredients were examined by the following methods. <Sample> The base of Formulation Example 8 containing 1% of kinetin, which is the active ingredient of the present invention, was used. Only the base was used as a control, and 1% pentadecanoic acid glyceride was used as a positive control. When examining the effect of combined use, the base of Formulation Example 8 was used in which 0.3% of kinetin and a known active ingredient were mixed at a predetermined concentration.
【0036】<方法>全背部休止期毛のddY系白色マ
ウス(雄、7週齢、体重32g)の背部毛を電気バリカ
ンで刈毛し、各試料を刈毛の翌日から被験部皮膚に1日
2回、週5日、1匹当り1回0.2ml塗布した。1試
料について動物1群10匹を使用した。発毛効果の判定
は、処置35日後の発毛動物数と発毛面積率を対照群と
比較することで行なった。発毛面積率は、被験部の写真
を切取り、処置0日後に対する35日後の重量比率で求
め、1群の平均を算出し対照群と比較した。なお、対照
群には基剤のみを、陽性対照として1%ペンタデカン酸
グリセリドを用いた。<Method> The back hair of a ddY white mouse (male, 7 weeks old, weight 32 g) with whole back resting hair was shaved with an electric clipper, and each sample was applied to the skin of the test area from the day after the hair cutting. 0.2 ml was applied twice a day, 5 days a week, once per animal. Ten animals per group were used for one sample. The hair growth effect was determined by comparing the number of hair growth animals and the area of hair growth 35 days after the treatment with the control group. The hair-growth area ratio was obtained by cutting out a photograph of the test area and calculating the weight ratio after 35 days to 0 days after the treatment and calculating the average of one group and comparing it with the control group. In the control group, only the base was used, and 1% pentadecanoic acid glyceride was used as a positive control.
【0037】<結果>表1ないし表4に各サンプルの効
果を示した。なお、対照である基剤のみの試験結果は、
発毛動物数が2/10、発毛面積率が15.2%であっ
た。本発明のカイネチンは単独配合で発毛効果が認めら
れるばかりでなく、カイネチンと他の公知の育毛有効成
分との併用においても、相乗的な発毛効果が認められ
た。<Results> The effects of each sample are shown in Tables 1 to 4. In addition, the test result of only the base material as a control is
The number of hair-growing animals was 2/10, and the hair-growth area ratio was 15.2%. The kinetin of the present invention was not only found to have a hair-growth effect when blended alone, but a synergistic hair-growth effect was also observed when kinetin was used in combination with other known hair-growth active ingredients.
【0038】[0038]
【表1】 [Table 1]
【0039】[0039]
【表2】 [Table 2]
【0040】[0040]
【表3】 [Table 3]
【0041】[0041]
【表4】 [Table 4]
【0042】[0042]
【発明の効果】本発明によれば、カイネチンを有効成分
とする育毛剤が提供され、この育毛剤は、毛髪の発毛促
進、および男性型脱毛症や円形脱毛症などの脱毛症の治
療に卓越した効果を発揮し得るものである。また、上記
カイネチンを、サイクリックアデノシンモノフォスフェ
ートおよびその誘導体、サイクリックグアノシンモノフ
ォスフェートおよびその誘導体、フォルスコリン、塩化
カルプロニウム、ペンタデカン酸グリセリド、ミノキシ
ジル、女性ホルモン、副腎皮質ホルモン、ビタミン類、
末梢血管拡張剤、細胞賦活剤、ならびに感光素からなる
群より選ばれる1種以上の化合物と併用することによっ
て相乗的な発毛促進効果を達成できる。INDUSTRIAL APPLICABILITY According to the present invention, there is provided a hair-growing agent containing kinetin as an active ingredient, which is used for promoting hair growth and treating alopecia such as androgenetic alopecia and alopecia areata. It is able to exert outstanding effects. Further, the above kinetin, cyclic adenosine monophosphate and its derivatives, cyclic guanosine monophosphate and its derivatives, forskolin, carpronium chloride, pentadecanoic acid glyceride, minoxidil, female hormone, adrenocortical hormone, vitamins,
When used in combination with one or more compounds selected from the group consisting of peripheral vasodilators, cell activators, and photosensitizers, a synergistic hair growth promoting effect can be achieved.
Claims (2)
とする育毛剤。1. A hair restorer comprising kinetin as an active ingredient.
モノフォスフェートおよびその誘導体、サイクリックグ
アノシンモノフォスフェートおよびその誘導体、フォル
スコリン、塩化カルプロニウム、ペンタデカン酸グリセ
リド、ミノキシジル、女性ホルモン、副腎皮質ホルモ
ン、ビタミン類、末梢血管拡張剤、細胞賦活剤、ならび
に感光素からなる群より選ばれる1種以上の化合物を有
効成分とすることを特徴する育毛剤。2. Kinetin, cyclic adenosine monophosphate and its derivative, cyclic guanosine monophosphate and its derivative, forskolin, carpronium chloride, pentadecanoic acid glyceride, minoxidil, female hormone, adrenocortical hormone, vitamins, A hair restorer characterized by comprising, as an active ingredient, one or more compounds selected from the group consisting of peripheral vasodilators, cell activators, and photosensitizers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP634593A JPH06211632A (en) | 1993-01-19 | 1993-01-19 | Hair-growing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP634593A JPH06211632A (en) | 1993-01-19 | 1993-01-19 | Hair-growing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06211632A true JPH06211632A (en) | 1994-08-02 |
Family
ID=11635789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP634593A Withdrawn JPH06211632A (en) | 1993-01-19 | 1993-01-19 | Hair-growing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06211632A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0873324A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair nourishment |
| JPH08127518A (en) * | 1994-09-07 | 1996-05-21 | Dai Ichi Seiyaku Co Ltd | Composition for hair |
| KR970032805A (en) * | 1995-12-07 | 1997-07-22 | 다카하시 미치나오 | Parenting |
| JP2005035903A (en) * | 2003-07-16 | 2005-02-10 | Lion Corp | Hair-restoring and growing agent composition |
| JP2006199648A (en) * | 2005-01-21 | 2006-08-03 | Dai Ichi Seiyaku Co Ltd | Hair composition |
| JP2009298787A (en) * | 2008-06-06 | 2009-12-24 | Lvmh Recherche | Method for anti-aging cosmetic care by stimulation of survivin expression |
| US10123966B2 (en) | 2013-05-16 | 2018-11-13 | The Procter And Gamble Company | Hair thickening compositions and methods of use |
| US11045444B2 (en) | 2016-06-30 | 2021-06-29 | Plume Cosmetics Inc. | Composition and method for promoting eyelash and eyebrow growth exclusively containing naturally sourced ingredients |
-
1993
- 1993-01-19 JP JP634593A patent/JPH06211632A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0873324A (en) * | 1994-09-06 | 1996-03-19 | Kao Corp | Hair nourishment |
| JPH08127518A (en) * | 1994-09-07 | 1996-05-21 | Dai Ichi Seiyaku Co Ltd | Composition for hair |
| KR970032805A (en) * | 1995-12-07 | 1997-07-22 | 다카하시 미치나오 | Parenting |
| JP2005035903A (en) * | 2003-07-16 | 2005-02-10 | Lion Corp | Hair-restoring and growing agent composition |
| JP2006199648A (en) * | 2005-01-21 | 2006-08-03 | Dai Ichi Seiyaku Co Ltd | Hair composition |
| JP2009298787A (en) * | 2008-06-06 | 2009-12-24 | Lvmh Recherche | Method for anti-aging cosmetic care by stimulation of survivin expression |
| US10123966B2 (en) | 2013-05-16 | 2018-11-13 | The Procter And Gamble Company | Hair thickening compositions and methods of use |
| US11045444B2 (en) | 2016-06-30 | 2021-06-29 | Plume Cosmetics Inc. | Composition and method for promoting eyelash and eyebrow growth exclusively containing naturally sourced ingredients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5663160A (en) | Cosmetic or dermatological composition containing at least one saponin of the ginsenoside type, and its applications, especially for treating the hair | |
| JPH05320028A (en) | Hair-growing agent | |
| JPH07316023A (en) | Hair tonic | |
| JP2937446B2 (en) | Blackening agent to prevent gray hair | |
| JP3027302B2 (en) | Hair restoration / hair restoration | |
| US8901088B2 (en) | Composition for preventing or treating poliosis or vitiligo comprising a pueraria genus plant extract or puerarin | |
| KR20200076101A (en) | Natural hair growth agent and manufacturing method thereof | |
| EP0540854B1 (en) | Preparation for promoting hair growth | |
| HK1007379B (en) | Preparation for promoting hair growth | |
| JP4032246B2 (en) | White hair prevention and improvement agent | |
| EP0740930B1 (en) | Blood flow improver and cosmetic | |
| JP3689190B2 (en) | Hair nourishing agent | |
| JPH06192047A (en) | Hair tonic | |
| JPH09241137A (en) | Hair crowing and restoring agent | |
| JP3382135B2 (en) | External preparation for hair | |
| JP2002179584A (en) | Testosterone 5α-reductase inhibitor and androgen receptor binding inhibitor, hair preparation and skin cosmetic | |
| JP3382148B2 (en) | External preparation for head | |
| JP3536872B2 (en) | Hair restorer | |
| JP3542700B2 (en) | Head composition | |
| EP0679385A2 (en) | Hair revitalizing composition | |
| JPH10203935A (en) | Hair growth agent | |
| JPH01135711A (en) | Hair tonic | |
| JP3496896B2 (en) | Hair restorer and hair cosmetic | |
| JPH1017440A (en) | Hair growing and restoring agent | |
| JP2000264820A (en) | Composition for promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20000404 |